Cargando…
A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma
PURPOSE: This study was conducted to assess the pharmacokinetics and safety of enzastaurin in native Chinese patients with refractory solid tumors and lymphoma. METHODS: Eligible patients received 500 mg of enzastaurin orally once daily. The pharmacokinetics of enzastaurin and its metabolites were a...
Autores principales: | Li, Xueying, Fang, Xiaojie, Li, Su, Zhang, Weijing, Yang, Nong, Cui, Yimin, Huang, He, Cai, Ruiqing, Lin, Xiaoting, Fu, Xiaohong, Hong, Huangming, Lin, Tongyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951311/ https://www.ncbi.nlm.nih.gov/pubmed/26942463 http://dx.doi.org/10.18632/oncotarget.7875 |
Ejemplares similares
-
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
por: Padda, Sukhmani K., et al.
Publicado: (2011) -
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
por: Nwankwo, Nwabundo, et al.
Publicado: (2012) -
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008) -
Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules
por: Körner, A, et al.
Publicado: (2010) -
Inhibition of Glycogen Synthase Kinase 3 (GSK3) Increases the Cytotoxicity of Enzastaurin
por: Rovedo, Mark, et al.
Publicado: (2011)